Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Accumulated Expenses (2020 - 2025)

GeneDx Holdings has reported Accumulated Expenses over the past 6 years, most recently at $44.7 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $44.7 million for Q4 2025, up 258.91% from a year ago — trailing twelve months through Dec 2025 was $44.7 million (up 258.91% YoY), and the annual figure for FY2025 was $44.7 million, up 258.91%.
  • Accumulated Expenses for Q4 2025 was $44.7 million at GeneDx Holdings, up from $26.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for WGSWW hit a ceiling of $44.7 million in Q4 2025 and a floor of $7.3 million in Q2 2024.
  • Median Accumulated Expenses over the past 5 years was $18.4 million (2021), compared with a mean of $19.7 million.
  • Biggest five-year swings in Accumulated Expenses: crashed 59.04% in 2024 and later skyrocketed 285.52% in 2025.
  • GeneDx Holdings' Accumulated Expenses stood at $20.1 million in 2021, then grew by 1.02% to $20.3 million in 2022, then crashed by 40.05% to $12.2 million in 2023, then grew by 2.17% to $12.4 million in 2024, then skyrocketed by 258.91% to $44.7 million in 2025.
  • The last three reported values for Accumulated Expenses were $44.7 million (Q4 2025), $26.4 million (Q3 2025), and $28.1 million (Q2 2025) per Business Quant data.